Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions
作者: Sarina Levy-MendelovichTami LivnatAssaf Arie BargMona KidonTami Brutman-BarazaniGili Kenet
作者单位: 1Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
2The Israeli National Hemophilia Center and Thrombosis Unit, The Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel
3Pediatric Allergy Clinic, Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel
刊名: Blood Cells, Molecules and Diseases, 2020, Vol.80
来源数据库: Elsevier Journal
DOI: 10.1016/j.bcmd.2019.102370
关键词: Hemophilia AHemophilia BAllergyAnaphylaxisThrombin generation
英文摘要: Abstract(#br)Introduction(#br)Hemophilia is a rare bleeding disorder caused by a deficiency of the plasma coagulation factors VIII and IX (hemophilia A [HA] and hemophilia B [HB], respectively). Replacement therapy with clotting factor concentrates is the mainstay of treatment. Unlike in patients with HB, anaphylaxis in patients with HA is extremely rare.(#br)Methods(#br)A retrospective study of prospectively collected data on patients with hemophilia who experienced anaphylaxis was conducted in our center. Demographic and clinical data were collected, and laboratory workups that included thrombin generation were conducted.(#br)Results(#br)Our first patient underwent successful immune tolerance induction (ITI) following the administration of rituximab. The second patient was transitioned...
全文获取路径: Elsevier  (合作)
影响因子:2.259 (2012)

  • hemophilia 血友病
  • potential 
  • generation 世代
  • complication 纠纷
  • novel 长篇小说